openPR Logo
Press release

Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 Report

05-07-2018 08:04 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Cancer Immunotoxins Market & Clinical Pipeline Insight

“Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020” Report Highlights:

* Introduction to Immunotoxins
* Cancer Immunotoxins Therapy Analysis
* Advantages of Immunotoxins upon other Anticancerous Drugs
* Applications of Immunotoxins to Multiple Cancer Therapies
* Global Cancer Immunotoxins Market Future Prospects
* Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase
* Global Cancer Immunotoxins Clinical Pipeline: 52 Cancer Immunotoxins
* Majority Cancer Immunotoxins in Preclinical Phase: 21 Drugs

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-Cancer-Immunotoxins-Market-&-Clinical-Pipeline-Insight-2020.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Introduction to Immunotoxins



2. Immunotoxins: The Three Generations & Advancements



3. Sources of Toxins

3.1 Plant Toxins

3.2 Bacterial Toxins



4. Production of Immunotoxins



5. Types of Immunotoxins

5.1 Anthrax Based Toxins

5.2 Diphtheria Toxin (DT) & DT Derivatives

5.3 Pseudomonas Exotoxin (PE) & PE Derivatives

5.4 Ribosome Inactivating Proteins Based Immunotoxins

5.4.1 Ricin

5.4.2 Saporin based Immunotoxins

5.4.3 Recombinant Constructs of RIP I Toxins

5.5 Ribonucleases based Immunotoxins

5.6 Proapoptotic Proteins as Targeted Immunotoxins



6. Cancer Immunotoxins Therapy Analysis

6.1 Immunotoxins for Hematologic Malignancies

6.1.1 Denileukin Diftitox (ONTAK, DAB389IL-2)

6.1.2 LMB-2 (anti-Tac[Fv]-PE38)

6.1.3 Moxetumomab Pasudotox

6.1.4 A-dmDT390-bisFv (UCHT1)

6.1.5 DT2219ARL

6.1.6 HuM195-Gelonin

6.2 Immunotoxins for Solid Tumors

6.2.1 SS1P

6.2.2 RG7787

6.2.3 Oportuzumab Monatox

6.2.4 VB6-845

6.2.5 D2C7-(scdsFv)-PE38KDEL



7. Advantages of Immunotoxins upon other Anticancerous Drugs



8. Applications of Immunotoxins

8.1 Immunotoxins against Solid Tumors

8.1.1 Immunotoxin against Colon Carcinoma

8.1.2 Immunotoxin against Breast Cancer & Sarcoma

8.1.3 Immunotoxin against Glioma & Head & Neck Squamous Cell Carcinoma

8.1.4 Immunotoxin against Prostate & Lung Cancer

8.2 Immunotoxins against Leukemias

8.3 Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs



9. Global Cancer Immunotoxins Market Outlook

9.1 Current Market Scenario

9.2 Cancer Immunotoxins Clinical Pipeline Overview



10. Global Cancer Immunotoxins Market Dynamics

10.1 Favorable Parameters

10.1.1 Large Segment of Patient Still Devoid of Appropriate Medication

10.1.2 Cancer: A Severe Pathological Condition

10.1.3 Unmet Requirement of Completely Curative Agents

10.1.4 Unwanted Effects of the Existing Drugs

10.2 Commercialization Challenges

10.2.1 Stern Regulatory Guidelines: A Major Hurdle

10.2.2 Never Ending Phase of Research & Development

10.2.3 Conduction of Clinical Trials

10.2.4 Funding Research & Development: A Super Costly Affair

10.2.5 Immunogenicity of Immunotoxins



11. Global Cancer Immunotoxins Market Future Prospects



12. Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase

12.1 Research

12.2 Preclinical

12.3 Phase-I

12.4 Phase-I/II

12.5 Phase-II

12.6 Phase-II/III

12.7 Phase-III



13. Discontinued & No Development in Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase

13.1 No Development Reported

13.2 Discontinued

13.3 Suspended



14. Competitive Landscape

14.1 AbbVie

14.2 AbGenomics

14.3 Agensys

14.4 Ambrx

14.5 Amgen

14.6 AREVA Med

14.7 Bayer HealthCare

14.8 Biotest

14.9 Celldex Therapeutics

14.10 CuraGen Corporation

14.11 Genentech

14.12 Genmab

14.13 Heidelberg Pharma

14.14 ImmunoGen

14.15 Neurocrine Biosciences

14.16 Research Corporation Technologies

14.17 Sanofi

14.18 Seattle Genetics

14.19 Sorrento Therapeutics

14.20 Spirogen

Figure 2-1: Immunotoxins & Their Recombinant Forms

Figure 3-1: Sources of Toxins

Figure 4-1: Steps Involved in Production of Immunotoxins

Figure 5-1: Different Types of Immunotoxins

Figure 5-2: Mechanism of Action of Anthrax Based Immunotoxins

Figure 5-3: Composition of the Diphtheria Derived Toxins

Figure 5-4: Steps Involved in Apoptosis by Diphtheria Derived Immunotoxins

Figure 5-5: Domains of PE with Their Specificities

Figure 5-6: Mode of Apoptosis Taken by Pseudomonas Exotoxin (PE) & PE Derivatives

Figure 6-1: Major Targets of Immunotoxins as Anticancer Agents

Figure 6-2: Some of Important Immunotoxins Targeting Hematological Malignancies

Figure 6-3: Some of Important Immunotoxins Targeting Solid Tumors

Figure 8-1: Major Applications of Immunotoxins

Figure 9-1: Cancer Immunotoxins Pipeline by Phase (%), 2016

Figure 9-2: Cancer Immunotoxins Pipeline by Phase (Numbers), 2016

Figure 9-3: Cancer Immunotoxins Pipeline by Phase (%), 2016

Figure 9-4: Cancer Immunotoxins Pipeline by Phase (Numbers), 2016

Figure 10-1: Favorable Parameters for Global Cancer Immunotoxins Market

Figure 10-2: Commercialization Challenges for Global Cancer Immunotoxins Market

Figure 14-1: AbGenomics - Clinical Pipeline

Figure 14-2: Amgen - Clinical Pipeline

Figure 14-3: Biotest – Clinical Pipeline

Figure 14-4: Genmab - Clinical Pipeline

Figure 14-50: Genmab - Clinical Pipeline

Figure 14-6: Neurocrine Biosciences – Clinical Pipeline

Figure 14-7: Sorrento Therapeutics – Clinical Pipeline



Table 5-1: Immunotoxins in Clinical Development using Diphtheria as a Toxin Moiety

Table 5-2: Clinically evaluated/under evaluation PE-based Immunotoxins against Hematologic Malignancies

Table 5-3: Clinically evaluated/under evaluation PE-based Immunotoxins against Solid Tumors

Table 5-4: Clinical Trials in Patients with Saporin Containing Immunotoxins

Table 6-1: Immunotoxins for Leukemia

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 Report here

News-ID: 1040840 • Views: 199

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Immunotoxin

Global Immunotoxins Market Set for Rapid Growth and Trend, by 2023
Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin. Chemical conjugation of antibody to whole protein toxin creates immunotoxins, lacking of its natural binding domain. Immunotoxins are created in Escherichia coli that are distorted with a plasmid encoding the recombinant toxin. Harvesting
Global Immunotoxins Market - Industry Size, Share, Growth, Trends and Forecast 2 …
"The Report Immunotoxins Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin.
Download Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 Repo …
Immunotoxins are new generation chemotherapeutic agents innovated to include the specificity of monoclonal antibody and cytotoxicity of toxins extracted from plant or bacterial source. The targeting moiety carries the specificity of the antibody and is directed to the target where it either binds to the cell surface antigen, receptor or the ligand of the targeted disease. Cytotoxicity is mediated by the protein toxins, which maybe protein at times. The cytotoxic part
Immunotoxins Market Research Report | Growth Prospects, Key Opportunities, Trend …
Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin. Chemical conjugation of antibody to whole protein toxin creates immunotoxins, lacking of its natural binding domain. Immunotoxins are created in Escherichia coli that are distorted with a plasmid encoding the recombinant toxin. Harvesting
Cancer Immunotoxins Market Cancer Immunotoxins Clinical Pipeline Report 2020
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Immunotoxins 2. Immunotoxins: The Three Generations & Advancements 3. Sources of Toxins 3.1 Plant Toxins 3.2 Bacterial Toxins 4. Production of Immunotoxins 5. Types of Immunotoxins 5.1 Anthrax Based Toxins 5.2 Diphtheria Toxin (DT) & DT Derivatives 5.3 Pseudomonas Exotoxin (PE) & PE Derivatives 5.4 Ribosome Inactivating Proteins Based Immunotoxins
Global Cancer Immunotoxins Market Sales Revenue Clinical Trials Pipeline Report …
Immunotoxins are new generation chemotherapeutic agents innovated to include the specificity of monoclonal antibody and cytotoxicity of toxins extracted from plant or bacterial source. The targeting moiety carries the specificity of the antibody and is directed to the target where it either binds to the cell surface antigen, receptor or the ligand of the targeted disease. Cytotoxicity is mediated by the protein toxins, which maybe protein at times. Download Report: https://www.kuickresearch.com/report-Global-Cancer-Immunotoxins-Market-&-Clinical-Pipeline-Insight-2020.php For Report